Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIGHTY: Risankizumab in Pediatric Ulcerative Colitis
NCT07071519Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Primary completion
- Jul 2034
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in ulcerative colitis (UC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Serum Concentration at 64 weeks, Time to Maximum Serum Concentration at 64 weeks and 3 more. Started Jul 2025; status: recruiting.
02
Drugs
risankizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07071519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071519.